Company
Inozyme Pharma, Inc. (0001693011)
Standardized SEC financial data for Inozyme Pharma, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001693011 · Pharmaceutical Preparations.
Return on equity
-176.4%
Free cash flow
-$92.0M
Debt / equity
0.54×
Current ratio
3.56×
EPS (diluted)
$-1.62
Income statement
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| R&D expense | $16.2M | $46.5M | $37.7M | $47.8M | $54.8M | $83.2M |
| SG&A expense |
Balance sheet
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.6M | $159.9M | $111.8M | $127.9M | $188.6M | $113.1M |
| Total current assets |
Cash flow
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.8M | -$36.0M | -$48.2M | -$57.8M | -$70.7M | -$91.9M |
| Capital expenditures |
Get 0001693011 data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/0001693011/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/0001693011/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"